



2022 Winter Symposium and Reception

Saturday, December 10, 2022, 6:00 pm – 10:00 pm

The Troubadour Hotel
1111 Gravier St.
New Orleans, LA 70112

**Chinese American Hematologist &
Oncologist Network (CAHON)** www.cahon.org

美国华裔血液及肿瘤专家学会

Organizing Committee

Jing-Zhou Hou, MD, PhD
University of Pittsburgh Medical Center (Chair)

Hongtao Liu, MD, PhD
The University of Chicago Medical Center (Co-Chair)

J Christine Ye, MD, MS
University of Michigan (Co-Chair)

Bo Zhao, MD
Virginia Oncology Associates

Tian Zhang, MD, MHS
UT Southwestern Medical Center

Iris Zhi, MD, PhD
Memorial Sloan Kettering Cancer Center

Delong Liu, MD, PhD
New York Medical College



SARCLISA[®]
(isatuximab-irfc)

Injection for IV use | 500mg/25mL, 100mg/5mL

See the latest data for
SARCLISA + Kd

Explore the full results of the
IKEMA phase 3 trial at
sarclisahcp.com



Kd=Kyprolis (carfilzomib) and dexamethasone

SPONSORS & EXHIBITORS

2022 Corporate Partners



Diamond Sponsor



Silver Sponsor



Bronze Sponsor



Exhibitors

ADC Therapeutics
Amgen

**CANCER HAS
NO BORDERS.
NEITHER
DO WE**

Our mission is patients first through science and affordability. To help transform the biotechnology industry, creating impactful medicines that will be affordable and accessible to far more cancer patients around the world through science and business innovation.

8,000+

employees
(as of January 2022)

30+

filed or potentially registration
enabling trials ongoing, **95+** studies
in **40+** geographies

~50

commercial or clinical
stage assets

30

offices on
5 continents

20+

filings accepted for **10** medicines in
over **50** geographies, including 2nd
drug in U.S. and first in E.U.

9

approved medicines,
including **1** in the US

CONTENTS

Event Sponsors.....	page 1
About CAHON	page 3
Upcoming CAHON Events	page 5
Meeting Agenda.....	page 6
CAHON Young Investigator Awards	page 6
About Our Speakers	page 7



ABOUT CAHON

Founded by Chinese American Hematologists and Oncologists in 2005, the primary missions of CAHON are to foster communications amongst Chinese American medical professionals for the delivery of high-quality health care to patients with neoplastic and hematological diseases, and to promote medical information exchange between the United States and China in the field of hematology and oncology. CAHON strives to serve as a bridge among its members and between Chinese and American Hematology-Oncology communities for medical and educational exchange.

THE STORY BEHIND THE LOGO

CAHON'S logo was designed by Drs. Weijing Sun, Ke Liu, and Jeffrey Ye, under the supervision of the CAHON Board. The design has the following elements and takes the following considerations:

- The overall shape represents the globe.
- The blue, white, red and yellow represent the colors of two nations' flags. China and the US.
- The yellow and red stripes above the blue, represent bridges. One of CAHON's key missions is to serve as a bridge between Chinese American Hematology-Oncology communities for medical and educational exchange.
- The white space is in the shape of a heart. The hearts of our members continue to drive our mission to provide high quality patient care to everyone.

CAHON MEMBERSHIP

Apply to become a CAHON Membership at cahon.org

Value of a CAHON Membership

By joining CAHON you will have access to:

- A growing network of Chinese American professionals working in your field;
- A private WeChat group where you can submit clinical questions to respected colleagues who are knowledgeable in specific areas of hematology and oncology;
- Reduced or waived registration fees for all CAHON events and meetings along with priority hotel reservations;
- Members-only section of the CAHON website featuring the member directory; and
- Travel award opportunities.

MEMBERSHIP CATEGORIES

Regular/Active Membership

Associate Membership

Allied Membership

Visit cahon.org/membership for more information on membership.



Nasopharyngeal carcinoma (NPC):

FACING THE SURVIVAL FACTS

HEAD AND NECK CANCERS
**1-YEAR
PROGRESSION-FREE
SURVIVAL**

20%

R/M NASOPHARYNGEAL^{1*}

METASTATIC
OROPHARYNGEAL^{2†}

76%
HPV+

39%
HPV-

91% STAGE IV
LARYNGEAL^{3‡}

SEE THE
**NPC
FACTS**



NPCFacts.com/summer

Nasopharyngeal carcinoma (NPC) is a distinct cancer with a unique etiology and prognosis. Progression-free survival and overall survival data show poor outcomes in recurrent/metastatic disease, and limited effective treatment options highlight an unmet need in this area.

HPV = human papillomavirus, R/M = recurrent/metastatic.

*Results from a multicenter, randomized, open-label phase 3 trial of patients with recurrent or metastatic nasopharyngeal carcinoma (N=362).

†Results from a retrospective analysis of patients with HPV-positive and HPV-negative recurrent locoregional and distant metastatic oropharyngeal cancer (N=108).

‡Results from a retrospective study of patients with laryngeal squamous cell carcinoma (N=211).

References: 1. Zhang L, et al. *Lancet*. 2016;388:1883-1892. 2. Guo T, et al. *Cancer*. 2015;121:1977-1984. 3. Zhang Q, et al. *Front Oncol*. 11:606010.



© 2022 Coherus BioSciences, Inc.
All rights reserved. 0422-IO-P165

Save the Dates!

COMMUNITY ONCOLOGY FORUM (COF)

April 8, 2023
Las Vegas, NV

CAHON's Community Oncology Forum is a one-day program that is geared towards practicing oncologists/hematologists. The program attracts over 120 attendees in person and 50 attendees virtually, including about 100 practicing oncologists/hematologists. Attendees are both regional and from all states. Specifically, this program offers expert perspectives and practical insights into the latest therapies for all hematological and oncological diseases.

SUMMER SYMPOSIUM AND RECEPTION

June 3, 2023
The Metropolitan
Chicago, IL

Held in conjunction with ASCO, the Summer Symposium will offer expert perspectives and practical insights on current advancements in a variety of cancer treatments, as well as foster collaboration and provide a forum for interaction and collaboration between hematologists and oncologists.

10TH ANNUAL NEW YORK ONCOLOGY FORUM (NYOF)

October 7-8, 2023
New York, NY

The CAHON annual New York Oncology Forum (NYOF) is a one and a half day educational program that includes presentations on new developments and updates from the latest ASH, ASCO and SITC meetings including novel agents for Hematology and Oncology. 2023 will mark the 10th anniversary for this annual event and it draws more than 100 clinicians, researchers, medical students, clinical fellows as well as laboratory and health care related scientists working in the hematology and oncology.

WINTER SYMPOSIUM AND RECEPTION

December 2023
San Diego, CA

Held in conjunction with ASH, the Winter Symposium will offer expert perspectives and practical insights on current advancements in a variety of cancer treatments, as well as foster collaboration and provide a forum for interaction and collaboration between hematologists and oncologists.



Meeting Agenda

6:00 – 6:30 pm	Doors and Registration Open, Social Gathering, Visit Exhibit Booths
6:30 – 6:45 pm	Opening Remarks Hongtao Liu, MD, PhD, <i>CAHON Vice President</i> Sponsor Acknowledgement Jing-Zhou Hou, MD, PhD, <i>Chair of Organizing Committee</i>
6:45 – 8:05 pm	Scientific Presentations Moderators: Hongtao Liu, MD, PhD and J Christine Ye, MD, MS 6:45 – 7:05 pm Mantle Cell Lymphoma Michael Wang, MD, <i>MDACC</i> 7:05 – 7:25 pm Immunotherapy in Lymphoma Elizabeth Budde, MD, PhD, <i>City of Hope</i> 7:25 – 7:45 pm Chronic Lymphocytic Leukemia Yucui Wang, MD, PhD, <i>Mayo Clinic</i> 7:45 – 8:05 pm Novel Agents and Evolving Strategies in Myelofibrotic Neoplasm Jeffrey Pu, MD, PhD, <i>University of Arizona</i>
8:05 – 8:35 pm	Young Investigator Award Ceremony J Christine Ye, MD, MS Tian Zhang, MD, MHS Wanqing Zhi, MD, PhD <i>CAHON Academic Committee Chairs</i>  <u>YIA Award Winners</u> Suhu Liu, MD, PhD Jacqueline Wang, MD Zhengrui Xiao, MD Chen Zhang, MD Xiaomin Chen, MM Mengfei Ding, MD Xingting Hu, PhD Qingqing Wang, MD, PhD Zhuoya Yu, MD
8:35 – 8:50 pm	CAHON Update Ruirong Yuan, MD, PhD, <i>CAHON Board Chair</i> Hongtao Liu, MD, PhD, <i>CAHON Vice President</i>
8:50 – 10:00 pm	Social Gathering and Visit Exhibit Booths

Speakers



Dr. Michael Wang is the Puddin Clark endowed Professor in the Department of Lymphoma and Myeloma at MD Anderson Cancer Center in Houston, TX. Throughout his 20-year career at MD Anderson, his clinical and translational research has produced numerous scientific discoveries. His

clinical expertise is in hematological malignancies, including B-cell lymphoma and myeloma. His research on currently incurable mantle cell lymphoma (MCL) has led to the FDA approval of two Bruton's tyrosine kinase (BTK) inhibitors, ibrutinib and acalabrutinib, for relapsed or refractory MCL. He leads an international trial introducing CAR T-cell therapy to patients with relapsed/refractory MCL, and he has launched numerous investigator-initiated trials. His translational laboratory research studies have made far-reaching contributions to the lymphoma field. He has focused on identifying genetic and molecular signatures associated with MCL diagnosis and progression. He has characterized cellular and molecular heterogeneity within and across patients and delineated the dynamic evolution of both tumor and immune cell compartments in ibrutinib-sensitive and-resistant patients. To promote continued research and treatment of MCL, Dr. Wang established the Mantle Cell Lymphoma Program of Excellence at MD Anderson Cancer Center; it is the world's only center dedicated to the research and treatment of MCL and has become the largest referral center in the world. In addition, Dr. Wang is the founding and current Co-PI of the MD Anderson B-cell Lymphoma Moon Shot Program, with the immediate goal of using clinical, translational, and basic science approaches to double the cure rate of their B-cell lymphoma patients in the next 5-10 years. They are gathering information to fight lymphoma by detecting expression changes, gene mutations, and epigenetic modifications on a genome-wide scale, and using bioinformatics to predict responses to targeted therapy and immunotherapy.



Dr. Elizabeth Budde is a well-recognized clinical expert and researchers in the area of blood cancers. Her academic and clinical interests center on novel treatment for patients with lymphoma and leukemia. As a physician scientist, she leads a group of researchers in her laboratory designing and


investigating the use of immunotherapy to treat blood cancers and other diseases.

She leads the Immunotherapy Modality Team and is the executive medical director, Enterprise Immune Effector Cell Program at City of Hope. She also serves as a member on several national committees including National Comprehensive Cancer Network (NCCN) guidelines for B Cell Lymphoma, NCCN guidelines for Management of Immunotherapy-related Toxicities, and Alliance of American Cancer Institute CAR T Working Group.

Dr. Budde has received many honors and awards for her work. She was chosen as a Special Fellow in Clinical Research awardee by The Leukemia & Lymphoma Society, and an awardee of the Stop Cancer Foundation seed grant in 2016. She is also a recipient of the prestigious Damon Runyon Cancer Research Foundation Clinical Investigator Award (2014-2019). She has published many peer-reviewed


articles that have been featured in prominent journals including the Journal of Clinical Oncology, Lancet Oncology, Blood, Clinical Cancer Research, Journal of Immunology. She has also given many invited presentations at national and international meetings on her work.

Dr. Budde holds patents for new drugs currently under development in lymphoma and leukemia. She is the principal investigator of innovative translational research protocols and maintains a dynamic portfolio of clinical trials. Yucai Wang, MD, PhD (Co-Chair)



Dr. Yucai Wang is a lymphoma and CLL specialist at Mayo Clinic, Rochester, MN. He received his MD from Medical School of Nanjing University and PhD from The University of Texas MD Anderson Cancer Center. He completed his internal medicine residency at Rutgers and hematology/oncology

fellowship at Mayo Clinic. Dr. Wang has been a CAHON member since 2013 and is a 3-time winner of the CAHON young investigator award.



Dr. Jeffrey J. Pu received Ph.D. in Developmental Molecular Cell Biology from New York Medical College and MD from Shanghai Jiao-Tong University School of Medicine. He completed my Medicine Residency at Mount Sinai School of Medicine, then completed a NIH-supported experimental hematology

fellowship at pioneer Dr. Colvin M. Redman's laboratory and a clinical transfusion medicine/blood banking fellowship at the LFK Research Institute of New York Blood Center. He eventually completed Hematology/Oncology fellowship supported by NIH T32 training grant at Sidney Kimmel Comprehensive Cancer Center of Johns Hopkins University. He is certified as an expert of BMF diseases and a preferred hematologist consultant by the Aplastic Anemia & MDS International Foundation.

Dr. Pu's research interests include hematopoietic mechanism of hematological malignant disease progression, stem cell biology, biomarker translational research, cellular therapy, early phase clinical trials, and HCTT outcome-research. He is credited for first in the world identified and cloned hPD-1 gene and its immune modulating function; identified Kell blood gene-group expression pattern in early hematopoiesis and the cause of Kell alloimmune-induced severe fetal anemia; determined that PNH clone size of 25% as the golden diagnostic standard to predict the risk of significant hemolysis in aplastic anemia (AA); identified the origins of hypocellular myelodysplastic syndromes (MDS) and AA; and identified PIGN gene as a CIN suppressor in MDS progression and leukemic transformation.

Currently, Dr. Pu is an Associate Professor of Medicine (Tenured), Pathology, & Cancer Biology at the University of Arizona, Tucson, USA. He is the Director of Adult Hematopoietic Stem Cell Transplant and Cellular Therapy Program at the University of Arizona, Chief of Leukemias and Bone Marrow Failure Diseases Section, a Full Member of the UA NCI Designated Comprehensive Cancer Center, the Director of MDS Center of Excellence at UACC, Faculty Member of Arizona Biological & Biomedical Science Graduate Program, and the Co-Director of Cancer Biology Course (CBIO555/PHCL555) at CBIO Graduate Program.

Notes

Genentech
A Member of the Roche Group

GAZYVA[®]
obinutuzumab injection

 **POLIVY[™]**
polatuzumab vedotin-piiq
INJECTION FOR INTRAVENOUS USE 140MG

 **VENCLEXTA[®]**
venetoclax tablets 10mg, 50mg, 100mg



**Pharmacyclics/Janssen
is proud to support CAHON**



Zynlonta[®]
loncastuximab tesirine-lpyl
for injection, for intravenous use • 10mg

NOW WITH ONE-YEAR FOLLOW-UP DATA



ZYNLONTA is a registered trademark of ADC Therapeutics SA.
US-Covered LTX-00446, April 2022
© 2022 ADC Therapeutics SA. All rights reserved.

www.zynlontahcp.com

 **VENCLEXTA**[®]
venetoclax tablets 10mg, 50mg, 100mg

**For more information on VENCLEXTA,
visit VENCLEXTAHCP.COM**

abbvie

Genentech
A Member of the Roche Group

Distributed and marketed by AbbVie Inc., 1 North Waukegan Road, North Chicago, IL 60064
Marketed by Genentech USA, Inc., 1 DNA Way, South San Francisco, CA 94080-4990
©2019 AbbVie Inc. and Genentech USA, Inc.

 **VENCLEXTA**[®]
venetoclax tablets 10mg, 50mg, 100mg

US-VNCLL-190129/June 2019 Printed in USA



Chinese American Hematologist and Oncologist Network (CAHON)

555 East Wells Street, Suite 1100 • Milwaukee, WI 53202 USA

Phone: 1 414-918-9890 • Fax: 1 414-276-3349